Charles Pitman CFA
Stock Analyst at Barclays
(4.75)
# 690
Out of 5,058 analysts
234
Total ratings
69.6%
Success rate
15.4%
Average return
Main Sectors:
Stocks Rated by Charles Pitman CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: LONN Lonza Group AG | Reiterated: Buy | CHF 730.00 | CHF 603.80 | +20.90% | 35 | Oct 15, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Reiterated: Buy | €300.00 → €310.00 | €261.80 | +18.41% | 24 | Sep 30, 2026 | |
| EPA: DIM Sartorius Stedim Biotech S.A. | Reiterated: Buy | €240.00 → €250.00 | €219.40 | +13.95% | 20 | Sep 30, 2026 | |
| EPA: IPN Ipsen S.A. | Reiterated: Sell | €155.00 → €145.00 | €148.50 | -2.36% | 35 | Sep 28, 2026 | |
| SWX: BANB Bachem Holding AG | Reiterated: Hold | CHF 70.00 → CHF 80.00 | CHF 84.20 | -4.99% | 13 | Sep 8, 2026 | |
| SWX: PPGN PolyPeptide Group AG | Reiterated: Hold | CHF 44.31 | CHF 44.00 | +0.70% | 8 | Sep 8, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Reiterated: Buy | €60.00 → €70.00 | €44.41 | +57.62% | 18 | Sep 8, 2026 | |
| ETR: MRK Merck KGaA | Reiterated: Hold | €140.00 → €150.00 | €143.25 | +4.71% | 22 | Sep 8, 2026 | |
| EPA: BIM bioMérieux S.A. | Reiterated: Hold | €75.00 → €80.00 | €87.60 | -8.68% | 8 | Sep 7, 2026 | |
| BIT: DIA DiaSorin S.p.A. | Reiterated: Sell | €60.00 → €70.00 | €77.50 | -9.68% | 4 | Sep 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €48.00 → €50.00 | €53.00 | -5.66% | 16 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €13.50 → €12.50 | €10.09 | +23.89% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 75.00 | CHF 75.26 | -0.35% | 1 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $12.42 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $570.00 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $650 → $728 | $846.27 | n/a | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $20 | $7.54 | n/a | 1 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $283.40 | n/a | 1 | Jan 13, 2022 |
Lonza Group AG
Oct 15, 2026
Reiterated: Buy
Price Target: CHF 730.00
Current: CHF 603.80
Upside: +20.90%
Sartorius Aktiengesellschaft
Sep 30, 2026
Reiterated: Buy
Price Target: €300.00 → €310.00
Current: €261.80
Upside: +18.41%
Sartorius Stedim Biotech S.A.
Sep 30, 2026
Reiterated: Buy
Price Target: €240.00 → €250.00
Current: €219.40
Upside: +13.95%
Ipsen S.A.
Sep 28, 2026
Reiterated: Sell
Price Target: €155.00 → €145.00
Current: €148.50
Upside: -2.36%
Bachem Holding AG
Sep 8, 2026
Reiterated: Hold
Price Target: CHF 70.00 → CHF 80.00
Current: CHF 84.20
Upside: -4.99%
PolyPeptide Group AG
Sep 8, 2026
Reiterated: Hold
Price Target: CHF 44.31
Current: CHF 44.00
Upside: +0.70%
Bayer Aktiengesellschaft
Sep 8, 2026
Reiterated: Buy
Price Target: €60.00 → €70.00
Current: €44.41
Upside: +57.62%
Merck KGaA
Sep 8, 2026
Reiterated: Hold
Price Target: €140.00 → €150.00
Current: €143.25
Upside: +4.71%
bioMérieux S.A.
Sep 7, 2026
Reiterated: Hold
Price Target: €75.00 → €80.00
Current: €87.60
Upside: -8.68%
DiaSorin S.p.A.
Sep 7, 2026
Reiterated: Sell
Price Target: €60.00 → €70.00
Current: €77.50
Upside: -9.68%
Jul 30, 2026
Reiterated: Hold
Price Target: €48.00 → €50.00
Current: €53.00
Upside: -5.66%
Apr 22, 2026
Reiterated: Buy
Price Target: €13.50 → €12.50
Current: €10.09
Upside: +23.89%
Mar 11, 2026
Reiterated: Hold
Price Target: CHF 75.00
Current: CHF 75.26
Upside: -0.35%
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $12.42
Upside: -
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $570.00
Upside: -
Apr 28, 2025
Reiterated: Buy
Price Target: $650 → $728
Current: $846.27
Upside: n/a
Jan 4, 2024
Upgraded: Buy
Price Target: $20
Current: $7.54
Upside: n/a
Jan 13, 2022
Initiated Coverage: Buy
Price Target: n/a
Current: $283.40
Upside: n/a